Skip to main content
Premium Trial:

Request an Annual Quote

ESA Biosciences Gets $500K From NIH to Develop Metabolomics Platform

NEW YORK, March 24 (GenomeWeb News) - The US National Institutes of Heath has awarded Chelmsford, Mass.-based ESA Biosciences $538,619 to support the development of technologies to study metabolomics, GenomeWeb News has learned.

 

The grant, named "Integrating Lcec/Lcm in a Single Metabolomics Platform," was awarded to the company as part of the NIH Roadmap for Medical Research initiative, the company said in a statement.

 

"We will work toward developing a rugged platform that will incorporate both MS and EC detection in parallel, communicating with each other, to produce results that individually would not be possible," Ian Acworth, ESA vice president of HPLC products and services, said in the statement. The research will also incorporate ESA's new, breakthrough HPLC detection technology, the Corona Charged Aerosol Detector, the company added.

 

The company will conduct its research in collaboration with Oak Ridge National Laboratory, Applied Biosystems/MDS SCIEX, Millennium Pharmaceuticals, Cornell University Medical School, MassachusettsCollege of Pharmacy, BostonUniversityMedicalSchool, and Burke Medical Research Institute, ESA said.

The Scan

Not Immediately Told

The US National Institutes of Health tells lawmakers that one of its grantees did not immediately report that it had developed a more infectious coronavirus, Science says.

Seems Effective in Kids

The Associated Press reports that the Pfizer-BioNTech SARS-CoV-2 vaccine for children appears to be highly effective at preventing symptomatic disease.

Intelligence Warning on Bioeconomy Threats

US intelligence warns over China's focus on technologies and data related to the bioeconomy, the New York Times reports.

PLOS Papers on Campylobacteriosis Sources, Inherited Retinal Dystrophies, Liver Cancer Prognosis

In PLOS this week: approach to uncover source of Campylobacteriosis, genetic risk factors for inherited retinal dystrophies, and more.